文献速递肝病消化道肿瘤与早癌

Pi*MZ基因型是ACLD患者肝细胞癌发生的独立危险因素

The Alpha-1 Pi*MZ Genotype Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients With ACLD.
PubMed 文献 · Aliment Pharmacol Ther · 2026-01-23

本研究纳入815例接受HVPG测量和基因分型的晚期慢性肝病(ACLD)患者,其中30例(4%)携带SERPINA1 Pi*MZ基因型。中位随访47.3个月,68例发生肝细胞癌(HCC),Pi*MZ基因型与HCC风险增加独立相关(aSHR 3.31,95%CI 1.26-8.65,p=0.015)。

要点

  • Pi*MZ基因型在ACLD患者中与HCC风险增加独立相关。
  • 多变量分析校正年龄、性别、病因去除、AST、白蛋白和HVPG后,aSHR为3.31。
  • 校正aMAP评分后,Pi*MZ对HCC的影响仍显著(aSHR 2.94)。

核心结论

  • SERPINA1 Pi*MZ基因型与ACLD患者HCC发生风险增加相关,且独立于其他HCC危险因素。

研究设计与样本

  • 在维也纳肝脏血流动力学实验室接受HVPG测量和基因分型的ACLD患者队列,排除HCC患者,最终纳入815例。
  • 采用竞争风险分析,以HCC为感兴趣结局,死亡/肝移植为竞争事件。

主要发现

  • 815例患者平均年龄54±11岁,病毒性肝炎占53%,酒精相关肝病占37%,代谢功能障碍相关脂肪性肝病占10%。
  • 30例(4%)携带Pi*MZ基因型;中位随访47.3个月,68例发生HCC,其中Pi*MZ携带者8/30例。
  • 单变量和多变量分析中,Pi*MZ基因型均与HCC风险增加相关(aSHR 3.31,95%CI 1.26-8.65,p=0.015)。
  • 校正aMAP评分后,Pi*MZ基因型对HCC的影响仍显著(aSHR 2.94,95%CI 1.45-5.97,p=0.003)。

关键数值与推荐

  • Pi*MZ基因型与HCC风险的校正亚分布风险比(aSHR)为3.31(95%CI 1.26-8.65,p=0.015)。
  • 校正aMAP评分后,aSHR为2.94(95%CI 1.45-5.97,p=0.003)。

临床怎么用

  • 对ACLD患者可考虑进行SERPINA1 Pi*MZ基因型检测,以识别HCC高风险个体。
  • 携带Pi*MZ基因型的ACLD患者可能需要更密切的HCC监测。

局限性

  • 研究队列来自单中心血流动力学实验室,可能存在选择偏倚。
  • Pi*MZ基因型携带者样本量较小(30例),结果需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Homozygosity for the SERPINA1 Pi*Z deficiency allele is the culprit of alpha-1 antitrypsin deficiency-related liver disease, while harbouring a single Z-allele (e.g., the common Pi*MZ genotype) is the strongest genetic risk factor for advanced chronic liver disease (ACLD) and its progression. However, the impact of the Pi*MZ genotype on hepatocellular carcinoma (HCC) development in patients who have already progressed to ACLD has yet to be established. Thus, we investigated the impact of the Pi*MZ genotype on the development of HCC among longitudinally followed ACLD patients. METHODS: Patients undergoing hepatic venous pressure gradient (HVPG) measurement and genotyping at the Vienna Hepatic Haemodynamic Lab were included, excluding those with HCC. Competing risk analyses with HCC as the outcome of interest and death/liver transplantation as competing events were performed. RESULTS: We included 815 patients (mean age: 54 ± 11 years; viral hepatitis: 53%, alcohol-related liver disease: 37% and metabolic dysfunction-associated steatotic liver disease: 10%). Overall, 30 patients (4%) harboured the Pi*MZ genotype. During a median follow-up of 47.3 months, 68 patients developed an HCC (8/30 with Pi*MZ). The Pi*MZ genotype was associated with increased risks of HCC development in univariable as well as in multivariable analyses, accounting for other important factors (i.e., age, sex, removal of the primary aetiological factor, aspartate-aminotransferase, albumin and HVPG) identified in our study (adjusted subdistribution hazard ratio [aSHR]: 3.31 [95% confidence interval (CI): 1.26-8.65]; p = 0.015). The impact of the Pi*MZ genotype was confirmed adjusting for the aMAP score (aSHR: 2.94 [95% CI: 1.45-5.97]; p = 0.003). CONCLUSION: The SERPINA1 Pi*MZ genotype is associated with an increased risk of HCC development in patients with ACLD, independently of other HCC risk factors.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Balcar L, Semmler G, Scheiner B, et al. The Alpha-1 Pi*MZ Genotype Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients With ACLD. Aliment Pharmacol Ther. 2026. PMID: 41577636. doi:10.1111/apt.70530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。